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Abstract
Background: Recent studies have demonstrated a role for spinal p38 MAP kinase (MAPK) in the
development of chronic inflammation and peripheral arthritis and a role for GABA in the inhibition
of p38 MAPK mediated effects. Integrating these data suggests that GABA may play a role in
downregulating mechanisms that lead to the production of proinflammatory agents such as
interleukin-1, interleukin-6, and matrix metalloproteinase 3 – agents implicated in the pathogenesis
of rheumatoid arthritis (RA). Genetic studies have also associated RA with members of the p38
MAPK pathway.
Hypothesis: We propose a hypothesis for an inefficient GABA signaling system that results in
unchecked proinflammatory cytokine production via the p38 MAPK pathway. This model also
supports the need for increasing research in the integration of immunology and neuroscience.
Background
The impact of an immune response on the nervous
system has long been apparent, with multiple sclerosis
(MS), myasthenia gravis (MG), and neuropsychiatric
manifestations of systemic lupus erythematosus serving
as examples. While neuroendocrine modulation of the
immune system has been appreciated, the influence of
the nervous system on immune responses is not well
understood. The complex characters of a coordinated
immune response and the nervous/endocrine (electrical/
chemical) communication systems of the body compli-
cate research in this area; however, relationships between
the nervous and immune systems are essential for proper
function. Any entity would be compromised if its
defense and communication systems did not interact –
humans are no exception.
Rheumatoid arthritis (RA) is a common systemic inflam-
matory condition leading to symmetric, chronic synovial
inflammation, erosions, and joint destruction in some
patients. Its etiology is unclear but may result from an
environmental trigger in the context of genetic predisposi-
tion. There is literature precedent for neuroendocrine
involvement in RA pathogenesis [1] including suggestions
of neurotransmitters such as norepinephrine impacting
RA [2] and suggesting a role for the hypothalamic-pitui-
tary-adrenal axis in inflammation [3].
A recent article reported that inhibiting spinal cord p38
MAP kinase (MAPK) reduced joint inflammation in the rat
model of RA by an unknown mechanism [4]. Somatic affer-
ent pain signals received in the spinal cord result in stress-
induced kinase release, causing efferent signals that direct
mediators of inflammatory response. Spinal p38 MAPK
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inhibition lowered levels of the pro-inflammatory
mediators, interleukin 1 (IL-1), interleukin 6 (IL-6), and
matrix metalloproteinase 3 (MMP3), in the periphery,
thereby linking the central nervous system (CNS) with
peripheral immune responses [4]. IL-1 also functions as a
neuroendocrine modulator in animal models of RA [5], as
a cytokine contributing to joint destruction [6], and as a
product of pain facilitation responses of spinal cord glial
cells [7].
Proinflammatory cytokine production via p38 MAPK
appears to be dependent on tumor necrosis factor-alpha
(TNF-α) since administration of etanercept (TNF inhibi-
tor) blocks proinflammatory effects in rats [4]. If spinal
administration of a TNF inhibitor is effective in reducing
inflammatory disease with less systemic side-effects [8], it
may be an appropriate, albeit more cumbersome, delivery
method for this class of treatment.
p38 MAPK is an important intermediate in prostaglandin
release. Prostaglandins can modulate an inflammatory
response and sensitize neurons to pain. Activation of spi-
nal N-methyl-D-aspartic acid (NMDA) receptors results in
release of prostaglandins and mediators of thermal hyper-
algesia. p38 MAPK inhibition downregulates this process
[9], providing another example of immune regulation by
neuronal p38 MAPK. p38 MAPK is encoded by MAPK14
on Chromosome 6p21.3. Its alpha and gamma isoforms
are implicated in pathways leading to chronic inflamma-
tion [10]. p38 MAPK activates and interacts with immu-
nomodulators such as signal transducer and activator of
transcription 4 (STAT4), which has been recently associ-
ated with susceptibility to RA [11], other map kinase mol-
ecules (such as ERKs and MKKs), and NFκB. p38 MAPK,
TNF, NFκB, and STAT4 are potential pharmacological tar-
gets; therefore, research is intensifying to detect subtleties
of this pathway on inflammatory disease. One subtlety
that should be examined in this research is determining if
neurotransmitters participate in RA pathogenesis.
Hypothesis
We propose a model in which gamma-aminobutyric acid
(GABA), the primary inhibitory neurotransmitter of the
CNS, may downregulate p38 MAPK activity to reduce
peripheral production of proinflammatory cytokines in
joints affected by RA.
Afferent pain signals contribute to the CNS propagating
an inflammatory response that may influence the devel-
opment of peripheral arthritis [4]. Crosstalk between the
immune and nervous systems can inhibit p38 MAPK and
may downregulate a chronic inflammatory response.
GABA prevents release of IL-6 by inhibiting p38 MAPK in
rat glioma cells [12]. While the effects of GABA signaling
on release of other proinflammatory cytokines such as
IL-1 and TNF-α have not been examined, IL-1 is known
to impact GABA function [13].
GABA may reduce inflammation, or, conversely, deficient
GABA function may contribute to uncontrolled inflam-
mation. Such deficient function could likely occur at a
specific GABA receptor. GABAB receptors are metabotropic
and produce prolonged inhibitory signals, which make a
more likely candidate for impacting a chronic inflamma-
tory response. They differ from ionotropic GABA receptors
that utilize fast synaptic transmission. The GABAB receptor
is a heterodimer with subunits encoded by GABBR1 and
GABBR2. GABBR1 is encoded in the Major Histocompati-
bility Complex (MHC) extended class I region (6p21.3)
[14], an area of the MHC associated with MS, MG, Alzhe-
imer's disease, schizophrenia, narcolepsy, epilepsy, and
RA. While specific HLA-DRB1 alleles (MHC class II) con-
tribute strongly to RA susceptibility, possibly due to their
role in presenting arthritogenic peptides, GABBR1 poly-
morphisms are not in linkage disequilibrium with these
alleles (within publicly available HapMap data) as is
expected given the 3 Mb distance between the two loci.
Thus, observed genetic association to this region suggests
a potentially independent role for GABBR1 in genetic sus-
ceptibility to RA. GABBR1 polymorphisms have not been
experimentally characterized in RA patients but computa-
tional analyses suggest that some may influence alterna-
tive splicing [15] or protein structure [16]. GABBR1
encodes multiple isoforms and missense mutations [17]
that are implicated in other disease processes [18] further
supporting this possibility.
Since GABBR1 and MAPK14 are both encoded on 6p21.3,
their expression may be regulated together, which is com-
mon for functionally related genes in or near the MHC
[19,20]. Since GABA, which may downregulate inflamma-
tion, requires a receptor to signal, a GABBR1 polymorphism
may impair downstream inhibition of p38 MAPK. Other
molecules are known to influence p38 MAPK function in
an arthritic state, including map kinase family members
(such as ERK1/2) and NFκB [21], and likely also participate
in these complex interactions of RA pathogenesis.
Within that complex system, we propose a potential
mechanism that may contribute to chronic inflammation
in RA (Figure 1). A.) When synovial destruction begins,
afferent somatic fibers carry nociceptive impulses to the
spinal cord. B.) In the spinal cord, these pain and/or
cytokine signals activate p38 MAPK. C.) Spinal p38 MAPK
which then interacts with STAT4 or other molecules to
induce signals that upregulate additional proinflamma-
tory cytokine release such as IL-1, IL-6, or MMP3 in the
periphery [4,7]. (While the link between spinal cord
receptor signaling and peripheral immune responses is
not fully understood, there is precedent for suchJournal of Neuroinflammation 2008, 5:1 http://www.jneuroinflammation.com/content/5/1/1
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relationships [22]. For example, inhibited p38 MAPK sig-
naling in the spinal cord can trigger acetylcholine release
in the periphery [23].) D.) These proinflammatory mole-
cules produce additional joint destruction and excessive
immune response.
There are mechanisms that can negatively regulate this
pathway. An inhibitory signal to the spinal cord (ex.
GABA) may downregulate p38 MAPK and limit proin-
flammatory cytokine production [12]. This could reduce
an exacerbation of RA resulting from additional proin-
flammatory cytokines. Any variation affecting this nega-
tive regulation, such as a SNP allele or haplotype in
GABBR1, may allow p38 MAPK to proceed unchecked and
worsen RA.
Recent genetic evidence and functional studies in animals
suggest a neurological component to RA pathogenesis and
need for additional study. More insight into RA pathogen-
esis could also improve understanding of neurological
conditions. Proinflammatory cytokines, which exacerbate
synovial damage in RA, are present in excessive levels in
neurodegenerative diseases [24]. Understanding this
excess cytokine production in RA, or in neurodegenera-
tion, may assist research and ultimately treatment for the
other condition. One of these excessive proinflammatory
cytokines, IL-6, is implicated in improper beta-amyloid
processing during Alzheimer's disease (AD) due to its
effects on alpha-2-macroglobulin (A2M) [25]. A2M is a
protease inhibitor that clears beta-amyloid components;
when not functioning properly, plaques accumulate
Possible influence of GABA on p38 MAPK pathway in rheumatoid arthritis Figure 1
Possible influence of GABA on p38 MAPK pathway in rheumatoid arthritis. This figure illustrates a possible model 
for how GABA can inhibit the production of proinflammatory cytokines. All molecules are listed by their official gene name.Journal of Neuroinflammation 2008, 5:1 http://www.jneuroinflammation.com/content/5/1/1
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contributing to AD [26]. A2M is also a cytokine
transporter that is overly consumed in synovial fluid of RA
patients [27], causing an accumulation of materials
(cytokines) and contributing to disease. These two patho-
genic mechanisms use the same molecule (A2M) in a sim-
ilar manner (resulting in accumulation of materials):
studying the mechanism in one disease may help under-
standing pathogenesis of the other disease.
Implications
In summary, inhibition of p38 MAPK can limit joint
inflammation [4], and GABA can reduce p38 MAPK sign-
aling [12]. However, no direct link has been reported
between GABA and joint inflammation. We hypothesize
that GABA may influence RA pathogenesis via the p38
MAPK pathway as depicted in Figure 1.
One difficulty in establishing these links (i.e. relating
GABA to immune system physiology) is assembling the
resources and expertise needed to evaluate a neuroimmu-
nological question. While many researchers are focused
on neuroscience or immunology, few laboratories have
the experience to combine an understanding of neuronal/
glial molecular pathways and rheumatic/autoimmune
diseases. Furthermore, researchers in these areas do not
frequently collaborate. We would encourage additional
work on the role of spinal cord receptor signaling on the
development of RA, and we hope that suggesting a role for
GABA in the development of RA will not only encourage
the further integration of basic immunology into clinical
neuroscience but encourage the incorporation of basic
neuroscience into clinical immunology.
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